Last week the FDA issued a draft guidance on the use of social media in connection with the sale and distribution of drugs and biologics.  It’s called “Guidance for Industry: Fulfilling Regulatory Requirements for Postmarketing Submission of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics.  We’ve been remiss in not mentioning it.  Here’s the link.

Now, the draft guidance doesn’t address all that needs addressing.  But it is refreshing to see that the FDA is making an effort to issue such guidance — and we expect more — before the upcoming July 2014 deadline set by Congress.  If you haven’t already reviewed it, feel free to.  We intend to post our thoughts on it in the coming days.